Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02248675 · ClinicalTrials.gov registry record · NA
Adjunctive Brief Behavioral Treatment of Insomnia (BBTI) for Sleep Intervention (SI)
A NA study of Depression and Post Traumatic Stress Disorder, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT02248675: Completed NA study of Depression and Post Traumatic Stress Disorder, sponsored by VA Office of Research and Development.
NCT02248675 is a NA study of Depression and Post Traumatic Stress Disorder that has completed, run by VA Office of Research and Development. The registered enrollment target is 54 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02248675, a NA study of Depression and Post Traumatic Stress Disorder, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
There is a strong association between sleep disturbance and suicidal thoughts and behaviors. Sleep disturbance is also highly comorbid with other common conditions associated with suicide such as depression and posttraumatic stress disorder. Accordingly, this application focuses on improving sleep as a novel suicide prevention strategy that can be delivered to a broad range of Veterans. This pilot proposal specifically examines how Cognitive Behavioral Therapy for Insomnia, an efficacious treatment for insomnia, may reduce suicidal ideation in Veterans who also suffer from additional conditions. The proposal further suggests that adding this sleep intervention to usual care may further enhance overall care by increasing the utilization of recommended treatments for depression and posttraumatic stress disorder.
Primary Outcome
The entire Columbia Suicide Severity Rating Scale (C-SSRS) will be administered, but the investigators will use its' Suicidal Ideation Intensity scale (0-25 score range summed from five items, with higher scores indicating more severe suicidal ideation) as the primary outcome.
Conditions Studied
Interventions
- BEHAVIORAL CBT-I
- OTHER TAU
Study Locations (1)
New York
- Syracuse VA Medical Center, Syracuse, NY - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-01 |
| Phase | NA |
What the finished NCT02248675 record still lists
NCT02248675 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (93% lower).
The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which CBT-I is the first listed.
NCT02248675 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02248675 about?
NCT02248675 is a clinical study titled "Adjunctive Brief Behavioral Treatment of Insomnia (BBTI) for Sleep Intervention (SI)". There is a strong association between sleep disturbance and suicidal thoughts and behaviors. Sleep disturbance is also highly comorbid with other common conditions associated with suicide such as depression and posttraumatic stress disorder. Accordingly, this application focuses on improving sleep a...
What is the current status of trial NCT02248675?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2015-02. Estimated completion is 2016-01.
What conditions does trial NCT02248675 study?
This clinical trial studies the following conditions: Depression, Post Traumatic Stress Disorder, Insomnia, Suicidal Ideation.
What interventions are being tested in trial NCT02248675?
The interventions under investigation include: CBT-I (BEHAVIORAL), TAU (OTHER).
Who is sponsoring clinical trial NCT02248675?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02248675 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02248675's enrollment target sits among peer trials
54 457th of 679 higher than 219 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia